The American College of Chest Physicians’ “Therapy for Pulmonary Arterial Hypertension in Adults” was updated in March 2019. According to the new recommendations, which of the following treatments is recommended to improve the 6-minute walk distance among stable or symptomatic patients with pulmonary arterial hypertension (PAH) who are taking background therapy with ambrisentan?
Better luck next time
The American College of Chest Physicians also recommends that initial combination therapy with ambrisentan and tadalafil be prescribed to treatment-naïve patients with PAH who are World Health Organization functional class II or III to improve the 6-minute walk distance.
For more PAH content, visit the Resource Center.
Nice job!